Eli Lilly and Company $LLY Shares Sold by Covea Finance

Covea Finance trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,070 shares of the company’s stock after selling 4,400 shares during the quarter. Covea Finance’s holdings in Eli Lilly and Company were worth $30,573,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of LLY. Lazard Freres Gestion S.A.S. raised its stake in shares of Eli Lilly and Company by 114.3% in the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after acquiring an additional 41,222 shares in the last quarter. Precedent Wealth Partners LLC raised its position in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares in the last quarter. Central Pacific Bank Trust Division raised its position in Eli Lilly and Company by 25.8% in the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after purchasing an additional 1,843 shares in the last quarter. Capital Advisors Inc. OK boosted its stake in shares of Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after buying an additional 429 shares during the period. Finally, Family CFO Inc acquired a new position in shares of Eli Lilly and Company during the second quarter worth about $54,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on LLY shares. CICC Research lifted their price target on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. UBS Group restated a “neutral” rating on shares of Eli Lilly and Company in a research note on Thursday, December 18th. Finally, National Bankshares set a $1,286.00 price target on Eli Lilly and Company in a report on Monday, December 1st. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,155.36.

Eli Lilly and Company Stock Up 0.0%

LLY opened at $1,077.26 on Friday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The stock has a market capitalization of $1.02 trillion, a P/E ratio of 52.70, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37. The business’s 50-day simple moving average is $986.75 and its 200-day simple moving average is $841.14.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is presently 33.86%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.